Milestone is currently engaged in the development of new small molecule drugs for cardiovascular diseases.

Cardiovascular agent for atrial arrhythmias and angina

Milestone has a novel and potent short-acting calcium channel antagonist in preclinical development for the treatment of transient cardiovascular conditions such as angina and atrial arrhythmias.  Milestone's approach utilizes a well established mechanism of action that stems from the administration of compounds derived from a proven and safe drug class.  The company has used a focused medicinal chemistry approach to design and synthesize a limited number of compounds with the desired therapeutic activity and pharmacokinetic properties.